Earnings Call Transcript

Promising sounding exchange in relation to SPIRITUS:

Ed Arce
Hi Joe, so just one other question, as you look forward to the readouts of SPIRITUS at the end of the year and looking forward to discussing all that data with the FDA and moving forward broadly, I know you're in the process of beginning negotiations with potential partners both in Europe and potentially in Japan or greater Asia, so could you perhaps give us a little bit more details around where that stands now and how you see that going forward into next year?
Dr. Joseph Patti
Yes sure so, we don't really like to comment specifically on those sort of discussions, but what I can tell you is that we're reaching out as you indicated to both global, potential global partners and regional partner organizations that currently have respiratory sales franchises where we believe vapendavir would fit well. So that's the process of getting the program on the radar screen, having the initial dialogue which then will facilitate the more in-depth discussions once the data are available.